Bausch + Lomb (BLCO) Surges 14.5%: Is This an Indication of Further Gains?

Group 1 - Bausch + Lomb (BLCO) shares increased by 14.5% to $17.80, with a higher-than-average trading volume, contrasting with a 2.8% loss over the past four weeks [1][2] - The price surge is attributed to investor optimism following a Financial Times report indicating that Bausch + Lomb is considering a sale to address challenges from its spin-off from Bausch Health, with private equity firms likely interested [2][3] - The company is expected to report quarterly earnings of $0.16 per share, reflecting a year-over-year decline of 27.3%, while revenues are projected to be $1.17 billion, an increase of 15.8% from the previous year [3][4] Group 2 - The consensus EPS estimate for Bausch + Lomb has remained unchanged over the last 30 days, suggesting that the stock's price increase may not be sustainable without earnings estimate revisions [4] - Bausch + Lomb holds a Zacks Rank of 3 (Hold), indicating a neutral outlook, while another company in the same industry, Alignment Healthcare (ALHC), experienced a 3.2% decline in its last trading session [4][5] - Alignment Healthcare's consensus EPS estimate has decreased by 7.8% over the past month to -$0.14, representing a year-over-year change of 26.3% [5]